Table 3. Stratified analyses of the ELAC2 Ala541Thr polymorphism on prostate cancer risk.

Variables	na	Cases/controls	Thr allele vs Ala allele		AT vs AA		TT vs AA		AT/TT vs AA
			OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb
Total	14	5120/6209	1.22 (1.00–1.48)	0.131	1.23 (0.97–1.55)c	0.043	1.64 (0.59–4.57)	0.920	1.23 (0.99–1.53)	0.076
Ethnicities
Caucasian	7	3084/3333	1.19 (0.98–1.44)	0.084	1.20 (0.91–1.57)	0.063	1.67 (0.44–6.39)	0.667	1.19 (0.94–1.52)	0.139
Asian	4	805/553	4.44 (1.84–10.69)	0.941	4.27 (1.75–10.40)	0.928	2.62 (0.11–64.67)	—	4.42 (1.82–10.74)	0.937
African	1	243/296	1.22 (0.17–8.69)	—	1.22 (0.17–8.72)	—	—	—	1.22 (0.17–8.72)	—
Mixed	2	988/2027	0.96 (0.71–1.30)	0.859	0.98 (0.72–1.35)	0.848	1.37 (0.22–8.41)	0.763	0.95 (0.70–1.30)	0.899
Sources of cases
Sporadic	11	4134/5246	1.14 (0.93–1.38)	0.276	1.12 (0.91–1.37)	0.294	1.64 (0.51–5.31)	0.992	1.13 (0.92–1.38)	0.275
Familial	5	986/1441	1.46 (0.93–2.28)	0.210	1.51 (0.75–3.05)c	0.035	2.31 (0.30–17.59)	0.263	1.50 (0.84–2.68)	0.094

Abbreviations: CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.

^aNumber of comparisons.

^bP-value of Q-test for heterogeneity test.

^cA random-effects model was used when P-value for heterogeneity test was <0.05; otherwise, a fixed-effects model was used.